Panelists. Unique Perspectives on the Cost Burden of Diabetes in the United States.

Slides:

Advertisements

Similar presentations

Prevention of Type 2 Diabetes. Hyperglycemia in Type 2 Diabetes: Changing Treatment Paradigms.

Advertisements

Objective 2 Discuss recent data, guidelines, and counseling points pertaining to the older adults with diabetes.

Blood Glucose, Lipids, and Coronary Artery Disease: Emerging Strategies for Multimechanistic Treatment.

Updates and Perspectives in Diabetic Dyslipidemia

Optimizing Statin Therapy

Lifestyle and Professional CGM

Statin Selection Aimed to Reduce New-Onset DM Risk:

SGLT2 Inhibitors: What Do the Data Mean for My Patients?

Overview of Disparities

Access to NOAC Therapy:

SGLT2 Inhibitors and Their Clinical Impact:

Expert Panelists. Emerging CV Outcomes Trial Results: What Do They Mean for T2D Management?

Patient Case Discussions in T2D: What Intensification Plan Is Best?

What Comes Second?.

Updates on Outcomes for Novel T2D Therapies

Obesity and Dyslipidemia: How Would You Treat?

Clinical Advances in Type 2 Diabetes and Cardiovascular Risk

Selecting MM Therapy in Patients With Comorbidities

Early Type 2 Diabetes Mellitus: A Cardiovascular Disease

Goals. Achieving HbA1c Goals: Applying Guidelines to Intensify Therapy in Patients With Diabetes.

Panelists. One Size May Not Fit All: A New Aspirin Option for the High-Risk Patient.

Looking Beyond Glucose Control: Multifactorial Management of Type 2 Diabetes.

Incidence of CV Events in Subjects With T2D vs the Nondiabetic CAD Population

Blood pressure control: dependence on adherence

Metabolically Healthy Patients With Obesity

Statins and New-Onset Diabetes REAL Updates and Clinical Implications

Case Study. Managing Medication and Adherence in SIHD: Partnering With the Patient to Improve Care.

Are We Closer to Personalized Medicine in MS?

Diabetes and CV Risk Reduction: Cardiologists’ Perspectives on the Latest Outcomes Data.

Statins and Glucose Metabolism: Are All Agents Alike?

The future of urate-lowering strategies for gout

Seizures in the Elderly: Treatment and Special Considerations

Selected Causes of Cardiac Injury PEACE Trial High-Sensitivity Biomarker Substudy.

From Symptom Management to Communication in Advanced GI Cancers

Integrated Diabetes Care: How Can We Make the Best Use of New Technology?

Growing Diabetes Pandemic Worldwide

Access to NOAC Therapy:

A Journal Club on Lipid Management:

Statins and HIV:.

Trial analysis results comparing ACE inhibitors/ARBs with other antihypertensive drugs on renal disease progression End point Relative risk (95% CI) p.

Injectable Options as Add-Ons to Basal Insulin: Targeting PPG in Type 2 Diabetes Patients.

New Horizons in Adjunctive Type 1 Diabetes Management With SGLT Inhibitors.

Panelists. Secondary Prevention in Patients With ACS and Diabetes: How Can We Optimize Therapy?

The Cardiologist's Mindset in the Management of Diabetes and Coronary Artery Disease: Today and Tomorrow.

Antihyperglycemic Therapy

Goals. Weight Management Goals and Approaches in Patients With Type 2 Diabetes.

Incidence of CV Events in Subjects With T2D vs the Nondiabetic CAD Population

Program Goals Overview Is NEDA a Reasonable Target?

Novel Insulin/GLP-1 Combinations: Of Interest to the Primary Care Physician?

T2DM, CV Risk, and Modulating Risk With Glucose-Lowering Strategies

CAD and HF Often Coexist

Diabetes Pandemic. The Economics of Managing Patients With Diabetes and Coronary Artery Disease: A Payer Perspective.

Panelists. Cardiovascular Risk Modulation in Diabetes: Emerging Pathways and Insights.

Pharmacotherapy for Diabetic Coronary Disease:

Insulin in Diabetes Management: Effective Patient Selection Is Key

Statins, Obesity, and Hyperlipidemia

Glucose Management and Statin Therapy

The Rising Crisis of Prediabetes Diagnosis and Management of the Patient With Prediabetes.

Improving Effective Basal Insulin Use in Clinical Practice

Improving Adherence to Antiplatelet Therapy After an ACS Event

New Lipid-Lowering Guidelines

Program Goals Overview Is NEDA a Reasonable Target?

Statins and Glucose Metabolism: An Endocrinology Perspective

2015 EASD In Review: CV Risk management in t2dm

Obesity Management.

Glucose Management and Statin Therapy

Statin Selection in Patients With Pre-Diabetes: Case Considerations

Lipids, the Heart, and the Kidney

Fresh perspectives ON BASAL Insulins in diabetes care

Presentation transcript:

Unique Perspectives on the Cost Burden of Diabetes in the United States

Panelists

NHANES Study: A1C Control

US Population ≥18 with End-Stage Renal Disease From T2D

Visual Impairment Related to T2D

Diabetes Cost

Projecting the Future Diabetes Population: The Imperative for Change

Diabetes Prescription Drug Therapy Class Review

Cost-Effective Interventions

Incidence of T2D

Cost-Effectiveness of Lifestyle Modification or Metformin: DPP

Medication for Pre-T2D

YMCA Model of DPP in the Community

Measured Risk Factors for Teens

Measured Risk Factors Identified

Look AHEAD Trial

Trials of More vs Less Glucose Lowering (All used more/earlier insulin vs less/later insulin)

Medication Adherence

Have the Conversation

Key Resources to Share With Your Patients

Take Home Points: Summary

Abbreviations

References

References (cont)

References (cont)